The phase III HARMONi trial, published in Lancet Oncology, showed the investigational PD-1xVEGF bispecific antibody ivonescimab plus chemotherapy improved progression-free survival (6.8 vs 4.4 months; HR 0.52) and overall survival (16.8 vs 14.0 months; HR 0.79) in patients with EGFR-mutant NSCLC after progression on an EGFR TKI. Other research identified four distinct molecular groups in lung neuroendocrine neoplasms, including a highly aggressive 'supra-carcinoid' subtype. An upcoming WCLC26 presentation will show that in resectable NSCLC patients with a pCR after neoadjuvant immunochemotherapy, dissecting 3–6 nodal stations predicted better DFS.
“Progression-free survival: 6.8 vs 4.4 months, HR 0.52”
— @LeXiuning · HARMONi trial · View post ↗📌 Amplified by @KolPulseAI
“There arefour strikingly different molecular groups that vary in patient characteristics, genomic and transcriptomic profiles, microenvironment, and morphology.”
— @OncoThor · Lung NEN profiling · View post ↗📌 Amplified by @KolPulseAI
“In pCR pts: 3–6 dissected nodal stations (not LN count) predicted better DFS vs <3 or >6 stations”
— @HHorinouchi · Nodal assessment in NSCLC · View post ↗The phase III PANKU-Breast01 trial of the investigational agent iza-bren (Yizekang®) met its primary endpoint of progression-free survival (PFS) in a pre-specified interim analysis for patients with HR+/HER2- breast cancer. Separately, the breast oncology community is discussing the updated ASCO guideline for HR+/HER2- early breast cancer, with questions remaining about the optimal timing, treatments, and tools for risk estimation.
“Iza-bren (Yizekang®) met primary endpoint (PFS) in a pre-specified interim analysis of the PANKU-Breast01 (aka BL-B01D1-306) trial for patients with HR+/HER2- breast cancer.”
— @raffcolo · PANKU-Breast01 Trial · View post ↗📌 Amplified by @KolPulseAI
“I’ve spent two days reviewing @ASCO ’s updated HR+/HER2− eBC guideline, yet key questions remain: when, under which treatments, and with which tool should risk be estimated?”
— @dr_yakupergun · ASCO HR+/HER2- eBC Guideline · View post ↗📌 Amplified by @KolPulseAI
“Better treatments have pushed progression further away for many patients with HER2-positive breast cancer.”
— @DrYukselUrun · HER2+ Breast Cancer Progress · View post ↗The U.S. FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. Discussion in the GI oncology community is focused on the label's breadth, particularly the 'not candidates for multi-agent systemic therapy' clause, which may extend its use into the first-line setting for certain patients unfit for chemotherapy. Separately, BioNTech has ended a Phase 2 clinical trial in colorectal cancer.
“The label includes patients who received ≥1 prior systemic therapy, consistent with RASolute 302, but also patients who are “not candidates for multi-agent systemic therapy.” Does this effectively extend the approval into the first-line setting for patients considered unfit for multi-agent chemotherapy?”
— @dr_yakupergun · Daraxonrasib approval label · View post ↗📌 Amplified by @KolPulseAI
“⭐️Really loving the wording in the daraxonrasib FDA approval. Clear autonomy for physicians, centered on patient needs. 👉🏼“The approval is for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy””
— @VivekSubbiah · Daraxonrasib FDA approval · View post ↗
“The only downside here is the price.. At ~$40k/mo supply, that's $480k/year.”
— @mukundiyngr · Daraxonrasib cost · View post ↗📌 Amplified by @KolPulseAI
“One day after daraxonrasib’s FDA approval, a new study suggests another way to block RAS signaling, a major cancer driver.”
— @ilyassahinMD · RAS signaling research · View post ↗📌 Amplified by @KolPulseAI
Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
A Korean phase 3 trial in post-prostatectomy salvage radiotherapy showed moderate hypofractionation (65 Gy/26 fx) provides comparable 4-year biochemical progression-free survival to conventional fractionation (80.1% vs 78.1%). Newly published 5-year follow-up data from the KEYNOTE-564 trial also continues to show an overall survival benefit for adjuvant pembrolizumab in kidney cancer.
“🚨 Salvage RT after prostatectomy in 26 visits instead of 33: same cancer control 🚨”
— @Adam_Weiner535 · Prostate Cancer Radiotherapy · View post ↗
“The 5-year follow-up from KY-564 now published in @Annals_Oncology --the first ever adjuvant trial in Kidney cancer continues to show a survival benefit now with OS at 5+years and in key subgroups!”
— @DrChoueiri · Adjuvant Kidney Cancer · View post ↗📌 Amplified by @KolPulseAI
“On the agenda: the LU-EBRT trial — neoadjuvant ¹⁷⁷Lu-PSMA + EBRT in high-risk prostate cancer.”
— @GenevieveLOOS12 · Prostate Cancer Theranostics · View post ↗A new publication in Clinical Lymphoma, Myeloma & Leukemia analyzing 2,117 paired samples found that the Binding Site Freelite and Siemens N Latex FLC serum free light chain assays are not interchangeable for individual patients at IMWG thresholds. Despite a strong correlation, the platforms differ in antibody design, calibration, and detection methods, which can influence reported values.
“The clinical message: strong correlation between assays does not mean they are interchangeable for individual patients.”
— @Abdallah81MD · Serum Free Light Chain Assays · View post ↗Multiple studies are highlighting bone health as a key survivorship issue in lymphoma, with data showing an increased risk of osteoporosis following first-line therapies and investigations into prophylaxis with agents like alendronate. Separately, final results from a Phase 2 trial of ruxolitinib plus azacitidine (RUXO+AZA) in patients with myelofibrosis were published.
“Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study”
— @mtmdphd · Lymphoma Survivorship · View post ↗
“👉👉👉Important brand new MPN paper alert 🚨 Final results ph2 RUXO+AZA for patients with Myelofibrosis led by Dr .@sankalparoraMD & Dr @MDmasarova & Dr .@Daver_Leukemia”
— @doctorpemm · Myelofibrosis · View post ↗
“4️⃣ long-term toxicity and #survivorship”
— @DrRaulCordoba · Survivorship · View post ↗